Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 613

The DOI matches its Crossref record, with a small difference in title or year.

The Efficacy and Safety of Dermagraft in Improving the Healing of Chronic Diabetic Foot Ulcers

Marston, William A., Hanft, Jason, Norwood, Paul, Pollak, Richard, for the Dermagraft Diabetic Foot Ulcer Study Group·2003·Diabetes Care
DOI 10.2337/diacare.26.6.1701
Open this paper in CoChat — free account

Abstract

OBJECTIVE—To determine if a human fibroblast–derived dermal substitute could promote the healing of diabetic foot ulcers. RESEARCH DESIGN AND METHODS—A randomized, controlled, multicenter study was undertaken at 35 centers throughout the U.S. and enrolled 314 patients to evaluate complete wound closure by 12 weeks. Patients were randomized to either the Dermagraft treatment group or control (conventional therapy). Except for the application of Dermagraft, treatment of study ulcers was identical for patients in both groups. All patients received pressure-reducing footwear and were allowed to be ambulatory during the study. RESULTS—The results demonstrated that patients with chronic diabetic foot ulcers of >6 weeks duration experienced a significant clinical benefit when treated with Dermagraft versus patients treated with conventional therapy alone. With regard to complete wound closure by week 12, 30.0% (39 of 130) of Dermagraft patients healed compared with 18.3% (21 of 115) of control patients (P = 0.023). The overall incidence of adverse events was similar for both the Dermagraft and control groups, but the Dermagraft group experienced significantly fewer ulcer-related adverse events. CONCLUSIONS—The data from this study show that Dermagraft is a safe and effective treatment for chronic diabetic foot ulcers.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/diacare.26.6.1701

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 16

  1. Sanders LJ: Diabetes mellitus: prevention of amputation. J Am Podiatric Assoc 84:322–328, 1994 · DOI
  2. Levin M: Prevention and treatment of diabetic foot ulcers. J Wound Ostomy Continence Nurs 21:129–146, 1998 · DOI
  3. Bloomgarden ZT: American Diabetes Association 60th Scientific Sessions, 2002: the diabetic foot. Diabetes Care 24:946–951, 2001 · DOI
  4. Ollendorf D, Kotsanos J, Wishner W: Potential economic benefits of lower-extremity amputation prevention strategies in diabetes. Diabetes Care 21:1240–1245, 1998 · DOI
  5. Loots MA, Lamme EN, Mekkes J, Middlekoop E: Differences in cellular infiltrate and extracellular matrix of chronic diabetic and venous ulcers versus acute wounds. J Invest Dermatol 111:850–857, 1998 · DOI · Paper page
  6. Lazarus G, Cooper DM, Knighton DR, Margolis DJ, Pecoraro RE, Rodeheaver G, Robson MC: Definitions and guidelines for assessment of wounds and evaluation of healing. Arch Dermatol 130:489–493, 1994 · DOI
  7. Hehenberger K, Heilborn K, Brismar K, Hansson A: Inhibited proliferation of fibroblasts derived from chronic diabetic wounds and normal dermal fibroblasts treated with high glucose is associated with increased formation of L-lactate. Wound Rep Regen 6:135–141, 1998 · DOI
  8. Falanga VF, Grinnel B, Gilchrist Y, Maddox T, Moshelle A: Experimental approaches to chronic wounds. Wound Rep Reg 3:132–140, 1995 · DOI
  9. Naughton G, Mansbridge J, Gentzkow G: A metabolically active human dermal replacement for the treatment of diabetic foot ulcers. Artificial Organs 21:1203–1210, 1997 · DOI
  10. Hanft JR, Surprenant MS: Healing of chronic foot ulcers in diabetic patients treated with a human fibroblast-derived dermis. J Foot Ankle Surg 41:291–299, 2002 · DOI
  11. Steed DL, and the Diabetic Foot Ulcer Study Group: Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic foot ulcers. J Vasc Surg 21:71–81, 1995 · DOI
  12. Veves A, Falanga V, Armstrong D, Sabolinski M, for the Diabetic Foot Ulcer Group: Graftskin, a human skin equivalent, is effective in the management of non-infected neuropathic diabetic foot ulcers: a prospective randomized multi-center clinical trial. Diabetes Care 24:290–295, 2001 · DOI · Paper page
  13. Pinney E, Liu K, Sheeman B, Mansbridge J: Human three-dimensional fibroblasts cultures express angiogenic activity. J Cell Physiol 183:74–82, 2000 · DOI
  14. Krejci-Papa NC, Hoang A, Hansbrough JF: Fibroblast sheets enable epithelialization of wounds that do not support keratinocyte migration. Tissue Engin 5:555–561, 1999 · DOI
  15. Kern A, Liu K, Mansbridge J: Modification of fibroblast interferon-gamma response by dermal fibroblast extracellular matrix. Ann N Y Acad Sci 961: 364–367, 2002 · DOI
  16. Falanga V: Classifications for wound bed preparation and stimulation of chronic wounds. Wound Rep Regen 8:347–352, 2000 · DOI

Cited by

Metadata

Authors
Marston, W. A., Hanft, J., Norwood, P., Pollak, R., & for the Dermagraft Diabetic Foot Ulcer Study Group
Affiliations
  • University of North Carolina School of Medicine, Chapel Hill, North Carolina
  • Foot & Ankle Institute of South Florida, South Miami, Florida
  • Valley Endocrine, Fresno, California
  • University of Texas Health Science Center, San Antonio, Texas; and the Dermagraft Joint Venture, La Jolla, California
Venue
Diabetes Care
Publisher
American Diabetes Association
Published
2003-06-01
Volume
26
Issue
6
Pages
1701-1705
ISSN
  • 0149-5992
  • 1935-5548
DOI
10.2337/diacare.26.6.1701
Cited by
613
References
0
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.